ConductScience.org, home

Paper36068002

Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates.

Chung E and 1 other. Investig Clin Urol, 2022. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates. Papers, record 36068002. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36068002

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates.
PubMed
Journal
Investig Clin Urol
PubMed
Year
2022
PubMed
Publication types
Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.63
iCite
Revised in PubMed
2025-07-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chung EErichttps://orcid.org/0000-0003-3373-3668
2Wang JJuan

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Microbial CollagenaseMajor topic
Penile IndurationMajor topic
Humans
Injections, Intralesional
Male
Patient Satisfaction
Penis
Prospective Studies
Treatment Outcome
Verapamil

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in37133744Male and Female Sexual Function and Dysfunction; Andrology.https://conductscience.org/library/papers/37133744

Source PubMed

Download CSV of comments and corrections

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130956106Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie's Disease.J Sex Med2019https://conductscience.org/library/papers/30956106PubMed
223376148Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.J Urol2013https://conductscience.org/library/papers/23376148PubMed
328923562Intralesional Injection of Collagenase Clostridium histolyticum May Increase the Risk of Late-Onset Penile Fracture.Sex Med Rev2018https://conductscience.org/library/papers/28923562PubMed
432542884
A clinical pathway for the management of Peyronie's disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association.
BJU Int2020https://conductscience.org/library/papers/32542884PubMed
525818264Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD).BJU Int2015https://conductscience.org/library/papers/25818264PubMed
617482941Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease.Urology2007https://conductscience.org/library/papers/17482941PubMed
728454897Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact.Sex Med Rev2018https://conductscience.org/library/papers/28454897PubMed
819199072Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study.Int Urol Nephrol2009https://conductscience.org/library/papers/19199072PubMed
928612401Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.BJU Int2017https://conductscience.org/library/papers/28612401PubMed
1023174244
A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome.
J Urol2013https://conductscience.org/library/papers/23174244PubMed
1126066402Peyronie's Disease: AUA Guideline.J Urol2015https://conductscience.org/library/papers/26066402PubMed
1228502596Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease.Urology2017https://conductscience.org/library/papers/28502596PubMed
1329733116Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study.Andrology2018https://conductscience.org/library/papers/29733116PubMed
1420666587Collagenase clostridium histolyticum for Dupuytren's contracture.Expert Opin Biol Ther2010https://conductscience.org/library/papers/20666587PubMed
1531475740A snapshot of intralesional verapamil injection in the treatment of Peyronie's disease today.Andrologia2019https://conductscience.org/library/papers/31475740PubMed
1630245025Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.J Sex Med2018https://conductscience.org/library/papers/30245025PubMed
1727215686Evidence-Based Management Guidelines on Peyronie's Disease.J Sex Med2016https://conductscience.org/library/papers/27215686PubMed
1827045265Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum for Peyronie's Disease.J Sex Med2016https://conductscience.org/library/papers/27045265PubMed
1923421851Peyronie's disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie's disease in a cell-culture strain system.J Sex Med2013https://conductscience.org/library/papers/23421851PubMed
2032345061A state-of-art review on collagenase Clostridium Histolyticum and Peyronie's disease: drug profile, clinical evidence and safety outcomes.Expert Opin Biol Ther2020https://conductscience.org/library/papers/32345061PubMed

See all 24 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ELN2006PubTator's text mininghttps://conductscience.org/library/genes/2006

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36068002

GET https://conductscience.org/api/papers/v1/36068002/references?page=2